Skip to main content

Table 3 Experiences and satisfaction with nintedanib and pirfenidone after three and six months of antifibrotic treatment

From: Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

  Month 3 Month 6
Nintedanib (n = 37) Pirfenidone (n = 46) Difference (95% CI) p-value Nintedanib (n = 37) Pirfenidone (n = 41) Difference (95% CI) p-value
Satisfaction with effectiveness 1.7 (1.6) 1.5 (1.6) 0.2 (− 0.5–0.9) 0.58 1.4 (1.7) 1.7 (1.9) 0.3 (− 1.1–0.6) 0.54
Satisfaction with side-effects 1.7 (2.0) 1.8 (2.2) 0.1 (− 1–0.9) 0.9 1.3 (1.9) 1.8 (2.2) 0.4 (− 1.4–0.5) 0.37
Satisfaction with ease of use 3.2 (1.6) 2.6 (1.6) 0.6 (− 0.1–1.3) 0.08 2.9 (1.4) 2.5 (1.9) 0.4 (−0.4–1.1) 0.3
Overall satisfaction with medication 2.2 (1.7) 1.9 (1.8) 0.2 (−0.5–1) 0.53 1.9 (1.7) 2.2 (2.0) 0.2 (−1.1–0.6) 0.58
Experiences with effectiveness 1.7 (1.0) 1.7 (0.9) 0.09 (−0.7–0.5) 0.75 2 (1.1) 1.8 (1.0) 0.2 (− 0.6–1) 0.55
Experiences with side-effects 3.1 (1.2) 2.9 (1.2) 0.3 (−0.3–0.8) 0.41 2.8 (1.2) 3.1 (1.1) 0.3 (−0.8–0.2) 0.25
Experiences with ease of use 3.9 (0.3) 3.8 (0.5) 0.1 (−0.05–0.3) 0.14 3.9 (0.3) 03.7 (0.6) 0.1 (−0.07–0.4) 0.18
Number of reported side-effects per patient 6.0 (3.5) 6.6 (4.6) 0.6 (−2.4–1.3) 0.55 5.7 (4.2) 5.7 (5.1) 0.05 (−2–2.1) 0.96
Severity score side-effects 9.9 (13.2) 9.8 (9.3) 0.1 (−4.8–5.1) 0.96 8.9 (9.5) 8.3 (9.0) 0.6 (−3.3–4.5) 0.75
  1. Data are presented as mean (SD). Experiences are scored on a scale from 0 to 4; a higher score corresponds with more positive experiences. Satisfaction is scored on a scale from − 5 to 5